JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Want to see JP:4552 full AI Analyst Report?
4552 Stock Chart & Stats
¥712.00
-¥21.00(-3.43%)
At close: 4:00 PM EST
¥712.00
-¥21.00(-3.43%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥824.00
Previous CloseN/A
Volume326.50K
Average Volume (3M)578.69K
Market Cap
¥69.05B
Enterprise Value¥105.40B
Total Cash (Recent Filing)¥13.18B
Total Debt (Recent Filing)¥40.10B
Price to Earnings (P/E)638.6
Beta0.89
Next Earnings
May 13, 2026EPS Estimate
-6.63Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)0.27
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.27
Price to Sales (P/S)1.81
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥785.00Price Target Upside10.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)11.83
Revenue Forecast (FY)¥38.80B
Bulls Say, Bears Say
Bulls Say
Niche Biologics & Contract ManufacturingJCR’s focus on rare-disease biologics and advanced drug delivery creates durable demand and pricing power in underserved therapeutic niches. Its contract manufacturing capabilities monetize production assets, diversifying revenue and linking operational scale to long-term commercial and CMO opportunities.
Healthy Asset Base / Equity RatioA healthy equity ratio indicates a solid asset base to support operations and R&D investment. Even with rising debt, this balance gives the company room to refinance or invest in capacity, preserving strategic optionality to develop or scale biologics over the medium term.
Positive Revenue Growth TrendA positive revenue growth rate suggests continued commercial traction for products or manufacturing services. Sustained top-line expansion supports economies of scale, potential margin recovery, and ability to fund development priorities without relying solely on external financing.
Bears Say
Negative Profitability / MarginsPersistent negative net and operating margins erode retained earnings and constrain reinvestment in R&D and commercialization. Ongoing unprofitability raises questions about pricing, cost structure, and competitiveness in key products, limiting long-term ability to self-fund growth initiatives.
Weak Cash GenerationNegative operating and free cash flows reduce the company’s capacity to fund operations, capital expenditures, and pipeline development internally. Over months, this increases dependence on external financing, which can dilute shareholders or raise borrowing costs and hamper strategic flexibility.
Rising LeverageAn increasing debt burden raises solvency and refinancing risk, particularly given weak profitability and negative cash flow. Higher leverage can constrain investment, increase interest obligations, and limit management’s ability to pursue acquisitions or expand manufacturing without improving cash generation.
JCR Pharmaceuticals Co., Ltd. News
4552 FAQ
What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥824.00 in the past 12 months.
What is JCR Pharmaceuticals Co., Ltd.’s market cap?
JCR Pharmaceuticals Co., Ltd.’s market cap is ¥69.05B.
When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is May 13, 2026 which is in 14 days.
How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
JCR Pharmaceuticals Co., Ltd. released its earnings results on Jan 28, 2026. The company reported ¥0.27 earnings per share for the quarter, beating the consensus estimate of -¥1.072 by ¥1.342.
Is JCR Pharmaceuticals Co., Ltd. overvalued?
According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Undervalued.
Does JCR Pharmaceuticals Co., Ltd. pay dividends?
JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
JCR Pharmaceuticals Co., Ltd.’s EPS estimate is -6.63.
How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥0.27 in its last earnings report, beating expectations of -¥1.072. Following the earnings report the stock price went down -2.519%.
Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
4552 Stock 12 Month Forecast
Average Price Target
¥785.00
▲(10.25% Upside)
Technical Analysis
Kyowa Kirin Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---